Journal
MEDCHEMCOMM
Volume 10, Issue 7, Pages 1068-1081Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c9md00018f
Keywords
-
Funding
- Swiss National Science Foundation [BSCGI0_157842]
- Swiss National Science Foundation (SNF) [BSCGI0_157842] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Peptides and small protein scaffolds are gaining increasing interest as therapeutics. Similarly to full-length antibodies, they can bind a target with a high binding affinity and specificity while remaining small enough to diffuse into tissues. However, despite their numerous advantages, small biotherapeutics often suffer from a relatively short circulating half-life, thus requiring frequent applications that ultimately restrict their ease of use and user compliance. To overcome this limitation, a large variety of half-life extension strategies have been developed in the last decades. Linkage to ligands that non-covalently bind to albumin, the most abundant serum protein with a circulating half-life of similar to 19 days in humans, represents one of the most successful approaches for the generation of long-lasting biotherapeutics with improved pharmacokinetic properties and superior efficacy in the clinic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available